Cancer moonshot needs funds, data
In calling for “a new national effort to ... cure cancer” during his State of the Union speech in January and labeling it a “cancer moonshot,” President Obama deliberately evoked John F. Kennedy’s 1961 commitment to landing a man on the moon.
But are the two efforts comparable? President Kennedy cited NASA’s need for a $ 5.4- billion budget aimed at a very specific goal; Obama is hoping Congress will heed his call for a $ 1billion launching fund for a much more nebulous and complicated goal.
But cancer and biomedical research experts speaking Monday at the Milken Global Conference in Beverly Hills, some of whom will be closely involved with the program, were hopeful that it would inspire new approaches to cancer research that could yield dividends well beyond the confines of the program itself.
“Get over the moonshot metaphor,” urged Greg Simon, the former Pfizer executive, aide to ex- vice president Al Gore, and cancer survivor who has been named executive director of the program. “President Kennedy didn’t say we’re going to study ‘ moonology’; he put a human being at the center of the program.”
The human approach has been missing from cancer research for years, researchers asserted; clinical trials have trouble signing up patients, worried about the possibility of painful side effects.
“Right now, clinical trials are ‘ experiments’ and the participants are ‘ subjects,’ ” said Kathy Hudson, deputy director for science, outreach and policy at the National Institutes of Health and the moderator at Monday’s panel. “Pa- tients don’t want to be ‘ subjected’ ” to tests. That resistance is one reason that only 3 to 4% of cancer patients are enrolled in clinical trials.
That’s a loss, because the patient’s viewpoint can help guide researchers and inject a sense of urgency. But the biggest obstacles to a successful campaign against cancer are lack of money, and lack of data. In recent years, the U. S. government has systematically starved its research agencies of needed funds for basic scientific research.
“We’re not lacking for ideas, we’re not lacking for talent,” NIH Director Francis Collins said at a separate panel. “We’re scaring away some of the talent.” Young researchers today face “the lowest success rate in history” at obtaining NIH grants — 16% of all grant applications are getting funded. NIH funding for biomedical research doubled to roughly $ 35 billion ( in 2012 dollars) from 1998 to 2003, he noted.
“Then the budget went stagnant, inf lation eroded our purchasing power,” and in 2013 was sliced by $ 1.5 billion in mid- year 2013 by the sequester, “from which we have really not quite recovered.... Young scientists in particular are feeling such a squeeze.”
Young researchers focus on individual research that can yield publishable papers to build their credits toward tenure and grant awards, administrators say, rather than toward collaborative projects that could yield results that are more scientifically valuable.
“We’re rewarding the wrong behavior,” said Anna Barker, a life sciences professor at Arizona State. What’s needed is more data- sharing, so that advances achieved by one project can be built on by others.
The panelists said they hope the moonshot will shift the incentives of research toward shared programs and shared data, but they acknowledged that tradition and commercial interests also have worked against that goal. Some of the world’s most prestigious scientific journals keep published papers behind expensive paywalls, not releasing them to the general public for a year or more after initial publication.
Meanwhile, the cost of developing cancer treatments and the profits to be made from blockbuster drugs also prompt some biomedical companies to hold their research close, though that may be changing.
“We are cooperating in ways that would not have happened a decade ago,” Robert Bradway, chairman and chief executive of Amgen, told the audience.